{
    "symbol": "ARGX",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-02 12:29:03",
    "content": " Across all of our efgartigimod studies, we also generated significant data in 2022 to broaden the scope of our safety database, which now includes more than 3,000 commercial patients globally, more than 1,300 clinical subjects, up to 19 cycles of intermittent cyclic dosing, and more than two years of weekly chronic dosing, all with a cumulative exposure of more than 1,000 patient years. Your line is open. Thanks for the question. Your line is open. Thanks for the question. Your line is open. Your line is open. Thanks for the question. Your line is open. Your line is open. Thanks for taking the question. Thanks for the question. Thank you for the question. Your line is open. Thanks for taking my question. Thank you for the question. Your line is open. Your line is open. Thanks for taking my question. Your line is open. Thanks for taking the question. Your line is open. Thanks for taking my question. Your line is open. Your line is open. Thanks for taking the question. Thanks for the question. Your line is open. Thank you for the question. Your line is open. Thanks for taking my question. Your line is open. Thanks for the question. Your line is open. Your line is open. Thank you for the question."
}